Physician profile
Holly Weeks
NPI 1104275387
$3,836.51
in general payments reported to CMS, 2019-2025
33 companies · $730 in 2025
The $730 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $985 · 2021: $644 · 2022: $453 · 2023: $413 · 2024: $405 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.08 | 2019-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $460.14 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $420.14 | 2020-2025 | |
| Lilly USA, LLC | $274.81 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $198.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $160.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $155.43 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.85 | 2020-2023 | |
| Amarin Pharma, INC. | $138.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $135.86 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.68 | 2020-2024 | Xifaxan |
| Biocryst US Sales Co., LLC | $115.00 | 2024 | Orladeyo |
| Astrazeneca Pharmaceuticals Lp | $97.20 | 2020-2025 | Airsupra, Farxiga |
| Biohaven Pharmaceuticals, INC. | $88.33 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.22 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $66.25 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $57.45 | 2019-2021 | |
| Abbott Laboratories | $53.79 | 2022-2024 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $51.38 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $40.94 | 2022 | |
| Dexcom, INC. | $34.52 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $32.67 | 2021 | |
| Gilead Sciences, INC. | $29.47 | 2020-2021 | |
| Sanofi Pasteur INC. | $29.13 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $21.24 | 2021 | |
| Axsome Therapeutics, INC. | $19.22 | 2025 | Symbravo |
| Intuity Medical INC | $17.82 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Dynavax Technologies Corporation | $15.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.02 | 2024 | Eliquis |
| Currax Pharmaceuticals LLC | $14.96 | 2025 | Contrave |
| Azurity Pharmaceuticals, INC. | $14.64 | 2023 | Horizant |
| Arbor Pharmaceuticals, INC. | $13.34 | 2020 | |
| Phathom Pharmaceuticals, INC. | $11.62 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.